Trial: 201609063

COG AALL1521 (INCB 18424-269) – A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2 Rearranged and/or JAK PathwayMutant Acute Lymphoblastic Leukemia

Phase

II

Principal Investigator

Hayashi, Robert

Disease Site

Lymphoid Leukemia

Learn more about this study at: clinicaltrials.gov